Abstract
Dr Brady has disclosed no financial relationship relevant to this commentary. This commentary does not contain a discussion of an unapproved/investigative use of a commercial product/device. The American Academy of Pediatrics recently published an updated policy statement on the use of palivizumab for respiratory syncytial virus (RSV) prophylaxis.1,2 This updated guidance is based on new information about the effects of gestational age and other risk factors on the incidence of RSV hospitalizations. Overall, there has been a decline in the incidence of hospitalizations for bronchiolitis in the United States.3 Among infants …
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
